Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 456

1.

Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.

Pan Y, Duron C, Bush EC, Ma Y, Sims PA, Gutmann DH, Radunskaya A, Hardin J.

PLoS One. 2018 May 22;13(5):e0190001. doi: 10.1371/journal.pone.0190001. eCollection 2018.

2.

Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.

Freret ME, Gutmann DH.

J Neurosci Res. 2018 Apr 28. doi: 10.1002/jnr.24250. [Epub ahead of print] Review.

PMID:
29704429
3.

Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth.

Pan Y, Xiong M, Chen R, Ma Y, Corman C, Maricos M, Kindler U, Semtner M, Chen YH, Dahiya S, Gutmann DH.

Genes Dev. 2018 Apr 1;32(7-8):491-496. doi: 10.1101/gad.310797.117. Epub 2018 Apr 9.

PMID:
29632086
4.

β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors.

Hirbe AC, Zhang X, Dahiya S, Godec A, Chrisinger J, Tao Y, Luo J, Gutmann DH.

Neuro Oncol. 2018 May 18;20(6):858-860. doi: 10.1093/neuonc/noy038. No abstract available.

PMID:
29596596
5.

A Conserved Circadian Function for the Neurofibromatosis 1 Gene.

Bai L, Lee Y, Hsu CT, Williams JA, Cavanaugh D, Zheng X, Stein C, Haynes P, Wang H, Gutmann DH, Sehgal A.

Cell Rep. 2018 Mar 27;22(13):3416-3426. doi: 10.1016/j.celrep.2018.03.014.

6.

Neurofibromatosis type 1.

Cimino PJ, Gutmann DH.

Handb Clin Neurol. 2018;148:799-811. doi: 10.1016/B978-0-444-64076-5.00051-X.

PMID:
29478615
7.

A genotype-phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1.

Morris SM, Gutmann DH.

Neurology. 2018 Feb 20;90(8):377-379. doi: 10.1212/WNL.0000000000005000. Epub 2018 Jan 24. No abstract available.

PMID:
29367450
8.

Optic Pathway Gliomas in Neurofibromatosis Type 1.

Campen CJ, Gutmann DH.

J Child Neurol. 2018 Jan;33(1):73-81. doi: 10.1177/0883073817739509.

PMID:
29246098
9.

Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M.

EMBO J. 2017 Dec 15;36(24):3650-3665. doi: 10.15252/embj.201796700. Epub 2017 Nov 10.

10.

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, Miettinen MM, Randall RL, Ratner N, Jumbé NL, Bakker A, Viskochil D, Widemann BC, Stewart DR.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx124. Review.

PMID:
29117388
11.

Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights.

Khatua S, Gutmann DH, Packer RJ.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26838. Epub 2017 Oct 19. Review.

PMID:
29049847
12.

Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner.

Zou J, Zhang B, Gutmann DH, Wong M.

Epilepsia. 2017 Dec;58(12):2053-2063. doi: 10.1111/epi.13923. Epub 2017 Oct 12.

PMID:
29023667
13.

Children with 5'-end NF1 gene mutations are more likely to have glioma.

Anastasaki C, Morris SM, Gao F, Gutmann DH.

Neurol Genet. 2017 Sep 22;3(5):e192. doi: 10.1212/NXG.0000000000000192. eCollection 2017 Oct.

14.

Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature.

Pan Y, Bush EC, Toonen JA, Ma Y, Solga AC, Sims PA, Gutmann DH.

Oncotarget. 2017 Apr 18;8(32):52474-52487. doi: 10.18632/oncotarget.17193. eCollection 2017 Aug 8.

15.

Neurodevelopmental disorders in children with neurofibromatosis type 1.

Vogel AC, Gutmann DH, Morris SM.

Dev Med Child Neurol. 2017 Nov;59(11):1112-1116. doi: 10.1111/dmcn.13526. Epub 2017 Aug 27. Review.

PMID:
28845518
16.

Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Maloney SE, Chandler KC, Anastasaki C, Rieger MA, Gutmann DH, Dougherty JD.

Autism Res. 2018 Jan;11(1):44-58. doi: 10.1002/aur.1853. Epub 2017 Aug 26.

17.

The Tropism of Pleiotrophin: Orchestrating Glioma Brain Invasion.

Gutmann DH.

Cell. 2017 Aug 24;170(5):821-822. doi: 10.1016/j.cell.2017.08.011.

PMID:
28841413
18.

Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA.

J Neuroophthalmol. 2017 Sep;37 Suppl 1:S23-S32. doi: 10.1097/WNO.0000000000000550. Review.

PMID:
28806346
19.

Updated nomenclature for human and mouse neurofibromatosis type 1 genes.

Anastasaki C, Le LQ, Kesterson RA, Gutmann DH.

Neurol Genet. 2017 Jul 26;3(4):e169. doi: 10.1212/NXG.0000000000000169. eCollection 2017 Aug. No abstract available.

20.

The power of the few.

Chen R, Pan Y, Gutmann DH.

Genes Dev. 2017 Jun 15;31(12):1177-1179. doi: 10.1101/gad.303453.117. Review.

21.

CNS Tumors in Neurofibromatosis.

Campian J, Gutmann DH.

J Clin Oncol. 2017 Jul 20;35(21):2378-2385. doi: 10.1200/JCO.2016.71.7199. Epub 2017 Jun 22. Review.

PMID:
28640700
22.

Caddyshack therapeutics: overcoming glioblastoma adaptation.

Gutmann DH.

Neuro Oncol. 2017 Oct 19;19(11):1429-1431. doi: 10.1093/neuonc/nox096. No abstract available.

PMID:
28637259
23.

Oligodendroglial myelination requires astrocyte-derived lipids.

Camargo N, Goudriaan A, van Deijk AF, Otte WM, Brouwers JF, Lodder H, Gutmann DH, Nave KA, Dijkhuizen RM, Mansvelder HD, Chrast R, Smit AB, Verheijen MHG.

PLoS Biol. 2017 May 26;15(5):e1002605. doi: 10.1371/journal.pbio.1002605. eCollection 2017 May.

24.

KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth.

Anastasaki C, Dahiya S, Gutmann DH.

Oncotarget. 2017 Jul 18;8(29):47574-47585. doi: 10.18632/oncotarget.17736.

25.

The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.

Solga AC, Toonen JA, Pan Y, Cimino PJ, Ma Y, Castillon GA, Gianino SM, Ellisman MH, Lee DY, Gutmann DH.

Oncotarget. 2017 Jul 18;8(29):47206-47215. doi: 10.18632/oncotarget.17589.

26.

Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer.

Chheda MG, Gutmann DH.

Cancer Cell. 2017 May 8;31(5):609-611. doi: 10.1016/j.ccell.2017.04.008.

27.

Increased Tissue Stiffness in Tumors from Mice with Neurofibromatosis-1 Optic Glioma.

Walter C, Crawford L, Lai M, Toonen JA, Pan Y, Sakiyama-Elbert S, Gutmann DH, Pathak A.

Biophys J. 2017 Apr 25;112(8):1535-1538. doi: 10.1016/j.bpj.2017.03.017.

28.

The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.

Blakeley JO, Bakker A, Barker A, Clapp W, Ferner R, Fisher MJ, Giovannini M, Gutmann DH, Karajannis MA, Kissil JL, Legius E, Lloyd AC, Packer RJ, Ramesh V, Riccardi VM, Stevenson DA, Ullrich NJ, Upadhyaya M, Stemmer-Rachamimov A.

Am J Med Genet A. 2017 Jun;173(6):1714-1721. doi: 10.1002/ajmg.a.38239. Epub 2017 Apr 24.

29.

MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models.

Hoye ML, Koval ED, Wegener AJ, Hyman TS, Yang C, O'Brien DR, Miller RL, Cole T, Schoch KM, Shen T, Kunikata T, Richard JP, Gutmann DH, Maragakis NJ, Kordasiewicz HB, Dougherty JD, Miller TM.

J Neurosci. 2017 May 31;37(22):5574-5586. doi: 10.1523/JNEUROSCI.3582-16.2017. Epub 2017 Apr 17.

30.

Human stem cell modeling in neurofibromatosis type 1 (NF1).

Wegscheid ML, Anastasaki C, Gutmann DH.

Exp Neurol. 2018 Jan;299(Pt B):270-280. doi: 10.1016/j.expneurol.2017.04.001. Epub 2017 Apr 6. Review.

PMID:
28392281
31.

Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival.

Pan Y, Smithson LJ, Ma Y, Hambardzumyan D, Gutmann DH.

Oncotarget. 2017 May 16;8(20):32977-32989. doi: 10.18632/oncotarget.16516.

32.

A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1.

Mahdi J, Shah AC, Sato A, Morris SM, McKinstry RC, Listernick R, Packer RJ, Fisher MJ, Gutmann DH.

Neurology. 2017 Apr 18;88(16):1584-1589. doi: 10.1212/WNL.0000000000003881. Epub 2017 Mar 22.

33.

Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma.

Chen Z, Feng X, Herting CJ, Garcia VA, Nie K, Pong WW, Rasmussen R, Dwivedi B, Seby S, Wolf SA, Gutmann DH, Hambardzumyan D.

Cancer Res. 2017 May 1;77(9):2266-2278. doi: 10.1158/0008-5472.CAN-16-2310. Epub 2017 Feb 24.

34.

Neurofibromatosis type 1.

Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ.

Nat Rev Dis Primers. 2017 Feb 23;3:17004. doi: 10.1038/nrdp.2017.4. Review.

PMID:
28230061
35.

Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1.

Monroe CL, Dahiya S, Gutmann DH.

Annu Rev Pathol. 2017 Jan 24;12:53-74. doi: 10.1146/annurev-pathol-052016-100228. Review.

PMID:
28135565
36.

Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma.

Ricker CA, Pan Y, Gutmann DH, Keller C.

Front Oncol. 2016 Dec 20;6:259. doi: 10.3389/fonc.2016.00259. eCollection 2016. Review.

37.
38.

Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.

Payne JM, Barton B, Ullrich NJ, Cantor A, Hearps SJ, Cutter G, Rosser T, Walsh KS, Gioia GA, Wolters PL, Tonsgard J, Schorry E, Viskochil D, Klesse L, Fisher M, Gutmann DH, Silva AJ, Hunter SJ, Rey-Casserly C, Cantor NL, Byars AW, Stavinoha PL, Ackerson JD, Armstrong CL, Isenberg J, O'Neil SH, Packer RJ, Korf B, Acosta MT, North KN; NF Clinical Trials Consortium.

Neurology. 2016 Dec 13;87(24):2575-2584. Epub 2016 Nov 9.

39.

A Novel Rac1-GSPT1 Signaling Pathway Controls Astrogliosis Following Central Nervous System Injury.

Ishii T, Ueyama T, Shigyo M, Kohta M, Kondoh T, Kuboyama T, Uebi T, Hamada T, Gutmann DH, Aiba A, Kohmura E, Tohda C, Saito N.

J Biol Chem. 2017 Jan 27;292(4):1240-1250. doi: 10.1074/jbc.M116.748871. Epub 2016 Dec 9.

40.

Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology.

Toonen JA, Solga AC, Ma Y, Gutmann DH.

J Exp Med. 2017 Jan;214(1):17-25. doi: 10.1084/jem.20160447. Epub 2016 Dec 6.

41.

Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Hirbe AC, Kaushal M, Sharma MK, Dahiya S, Pekmezci M, Perry A, Gutmann DH.

Cancer. 2017 Apr 1;123(7):1194-1201. doi: 10.1002/cncr.30455. Epub 2016 Nov 22.

42.

3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.

Anderson DM, Van de Plas R, Rose KL, Hill S, Schey KL, Solga AC, Gutmann DH, Caprioli RM.

J Proteomics. 2016 Oct 21;149:77-84. doi: 10.1016/j.jprot.2016.02.004. Epub 2016 Feb 13.

43.

Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).

Morris SM, Acosta MT, Garg S, Green J, Huson S, Legius E, North KN, Payne JM, Plasschaert E, Frazier TW, Weiss LA, Zhang Y, Gutmann DH, Constantino JN.

JAMA Psychiatry. 2016 Dec 1;73(12):1276-1284. doi: 10.1001/jamapsychiatry.2016.2600.

44.

Macrocephaly Is Not a Predictor of Optic Pathway Glioma Development or Treatment in Neurofibromatosis Type 1.

Morris SM, Monroe CL, Gutmann DH.

J Child Neurol. 2016 Dec;31(14):1540-1545. Epub 2016 Aug 31.

PMID:
27581847
45.

Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I.

Li K, Turner AN, Chen M, Brosius SN, Schoeb TR, Messiaen LM, Bedwell DM, Zinn KR, Anastasaki C, Gutmann DH, Korf BR, Kesterson RA.

Dis Model Mech. 2016 Jul 1;9(7):759-67. doi: 10.1242/dmm.025783. Epub 2016 Jun 2.

46.

Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival.

Smithson LJ, Gutmann DH.

Genes Dev. 2016 Jun 15;30(12):1383-8. doi: 10.1101/gad.279661.116.

47.

Contextual signaling in cancer.

Smithson LJ, Anastasaki C, Chen R, Toonen JA, Williams SB, Gutmann DH.

Semin Cell Dev Biol. 2016 Oct;58:118-26. doi: 10.1016/j.semcdb.2016.06.002. Epub 2016 Jun 3. Review.

48.

Exploring the genetic basis for clinical variation in neurofibromatosis type 1.

Gutmann DH.

Expert Rev Neurother. 2016 Sep;16(9):999-1001. doi: 10.1080/14737175.2016.1189329. Epub 2016 May 30. No abstract available.

49.

Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1.

Johnson KJ, Zoellner NL, Gutmann DH.

Cancer Epidemiol. 2016 Jun;42:53-9. doi: 10.1016/j.canep.2016.03.005. Epub 2016 Mar 25.

50.

ABCG1 maintains high-grade glioma survival in vitro and in vivo.

Chen YH, Cimino PJ, Luo J, Dahiya S, Gutmann DH.

Oncotarget. 2016 Apr 26;7(17):23416-24. doi: 10.18632/oncotarget.8030.

Supplemental Content

Loading ...
Support Center